Vaxxinity (NASDAQ:VAXX) Stock Price Up 13.2%

Vaxxinity, Inc. (NASDAQ:VAXX) was up 13.2% on Wednesday . The stock traded as high as $0.34 and last traded at $0.31. Approximately 177,007 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 1,321,025 shares. The stock had previously closed at $0.27.

Vaxxinity Stock Up 13.2 %

The company has a current ratio of 1.89, a quick ratio of 1.89 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $39.29 million, a PE ratio of -0.69 and a beta of 3.23. The firm has a 50 day moving average of $0.12 and a two-hundred day moving average of $0.49.

Institutional Investors Weigh In On Vaxxinity

A hedge fund recently bought a new stake in Vaxxinity stock. Ieq Capital LLC purchased a new stake in Vaxxinity, Inc. (NASDAQ:VAXX) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 83,262 shares of the company’s stock, valued at approximately $71,000. Ieq Capital LLC owned approximately 0.07% of Vaxxinity at the end of the most recent reporting period. Hedge funds and other institutional investors own 82.95% of the company’s stock.

Vaxxinity Company Profile

Vaxxinity, Inc, a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy.